MA-PRECISELY
21.6.2022 16:02:10 CEST | Business Wire | Press release
Precisely, the global leader in data integrity, today launched its new Precisely Data Integrity Suite – bringing the latest innovation in data integrity to the market. Announced at the company’s Trust ’22 event, the Data Integrity Suite is composed of seven interoperable SaaS modules that can be deployed individually, or seamlessly combined to deliver exponential value – fuelling businesses with unparalleled levels of trusted data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005275/en/
The announcement comes at the same time as the latest IDC Spotlight paper on “Improving Data Integrity and Trust through Transparency and Enrichment,” shows that only 27% of data professionals say they completely trust their data. With 63% of organizations reporting that higher levels of data integrity make a positive impact on their business metrics 1 , the launch of the new Data Integrity Suite is a timely one.
“Data integrity is an imperative for every business, but the journey to achieving it is different for every organization. With the Precisely Data Integrity Suite, businesses can start anywhere, go at their own pace, and grow value at every step of their unique journey,” said Eric Yau, COO at Precisely. “Our unmatched breadth of data integrity capabilities and enrichment data, combined with our strategic services expertise, means that we can help businesses chart their path to data integrity and lead them along the way.”
The Suite’s Data Integration, Data Observability, and Data Governance modules are available for early access now for businesses looking to build a foundation of accuracy and consistency in their data:
-
Data Integration
:
enables organizations to break down silos by quickly building streaming data pipelines that integrate data from core transaction systems into modern data platforms, driving innovation, and modernizing mission-critical infrastructure
-
Data Observability
:
a new entry from Precisely into this rapidly growing market, proactively and intelligently detects and surfaces data anomalies before they become costly downstream issues that could disrupt business
- Data Governance: delivers a business-friendly framework to find, understand, trust, and leverage critical data across an organization for better outcomes and insights, improved operations, and regulatory compliance
The following modules will join the Data Integrity Suite in the coming months:
-
Data Quality:
delivers data that is accurate, consistent, complete, and fit for purpose across operational and analytical systems
-
Geo Addressing:
unlocks valuable context by verifying, standardizing, cleansing, and geocoding addresses for more informed decision-making
-
Spatial Analytics:
derives and visualizes spatial relationships hidden in data to reveal critical context for better decisions
- Data Enrichment: enriches data with expertly curated datasets containing thousands of attributes for faster, more confident decisions
The Data Integrity Suite delivers access to trusted data at the speed of business and empowers organizations to make fast, confident decisions that drive growth, reduce costs, and manage risk. With a business-friendly user experience, it supports data democratization and self-service access to data for business and data users alike. Its unique Data Integrity Foundation includes a common data catalog that enables each module to build on metadata previously gathered by other modules, combining seamlessly to deliver maximum value to the customer.
“With the launch, Precisely is delivering on the vision they have painted for the market of integrating its capabilities into a modular, interoperable suite,” said Stewart Bond, Research Director at IDC. “Precisely has a strategic blend of technology and services within its portfolio to meet the needs of organizations with legacy and modern data environments that are wanting to compete in a digital-first world.”
“Businesses are increasingly investing in DataOps to continually improve the data they use for analytics and decision-making. The Precisely Data Integrity Suite’s end-to-end, integrated approach to data integration, data governance and quality, as well as location intelligence and data enrichment gives organizations all the tools and agility they need to automate and iterate on the integrity of their data,” said Anjan Kundavaram, CPO at Precisely. “The introduction of the Suite’s Data Observability module is essential for DataOps teams, allowing them to leverage AI and machine learning to gain critical insight into the health of their company’s data, monitor changes to patterns in that data, and proactively resolve potential issues.”
Financial services company, Degroof Petercam, a Precisely customer and participant in the Data Integrity Suite’s early access program, sees clear benefits of the new Data Observability module. “Observability is the missing piece today to give our data stewards access to data discovery insights without having to go to IT for queries or reports.” explains Jean-Paul Otte, Chief Data Officer at Degroof Petercam.
“The portfolio of data integrity assets that Precisely offers is the gold standard for building trusted data,” said Yau. “That same technology, recognized by industry analysts and relied upon by over 12,000 customers to address their data challenges today, is at the heart of the new Precisely Data Integrity Suite – providing the ultimate modular, interoperable, solution for organizations relying on data integrity across both legacy and modern cloud environments.”
Learn more about the new Data Integrity Suite and watch the 90-second video.
Data Integrity Suite Video Embed: To view this piece of content from www.youtube.com, please give your consent at the top of this page.
- IDC Spotlight, sponsored by Precisely, “Improving Data Integrity and Trust Through Transparency and Enrichment” (doc # US49285622, June 2022)
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005275/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
